Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice.
Anticancer Res
; 20(1A): 391-4, 2000.
Article
in En
| MEDLINE
| ID: mdl-10769685
ABSTRACT
The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-gamma production stimulated by IL-12. Since IFN-gamma has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors--batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylalanine
/
Protease Inhibitors
/
Thiophenes
/
Melanoma, Experimental
/
Metalloendopeptidases
/
Adjuvants, Immunologic
/
Interleukin-12
/
Angiogenesis Inhibitors
/
Neoplasm Proteins
/
Neovascularization, Pathologic
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Anticancer Res
Year:
2000
Document type:
Article